This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Jan;5(1):4-5.

doi: 10.1038/ncponc1007. Epub 2007 Nov 27.

Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma

Emilio Bajetta¹

Affiliations

PMID: 18043604
DOI: 10.1038/ncponc1007

Comment

Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma

Emilio Bajetta. Nat Clin Pract Oncol. 2008 Jan.

. 2008 Jan;5(1):4-5.

doi: 10.1038/ncponc1007. Epub 2007 Nov 27.

Author

Emilio Bajetta¹

Affiliation

¹ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milan 20133, Italy. emilio.bajetta@istitutotumori.mi.it

PMID: 18043604
DOI: 10.1038/ncponc1007

No abstract available

PubMed Disclaimer

Comment on

Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.
Kirkwood JM, Tarhini AA, Moschos SJ, Panelli MC. Kirkwood JM, et al. Nat Clin Pract Oncol. 2008 Jan;5(1):2-3. doi: 10.1038/ncponc1004. Epub 2007 Nov 13. Nat Clin Pract Oncol. 2008. PMID: 18030300 No abstract available.

Similar articles

Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.
Kirkwood JM, Tarhini AA, Moschos SJ, Panelli MC. Kirkwood JM, et al. Nat Clin Pract Oncol. 2008 Jan;5(1):2-3. doi: 10.1038/ncponc1004. Epub 2007 Nov 13. Nat Clin Pract Oncol. 2008. PMID: 18030300 No abstract available.
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Salès F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A. Eggermont AM, et al. Eur J Cancer. 2012 Jan;48(2):218-25. doi: 10.1016/j.ejca.2011.09.028. Epub 2011 Nov 5. Eur J Cancer. 2012. PMID: 22056637
Adjuvant therapy of melanoma: what's new?
Ascierto PA, Palmieri G, Daponte A, Melucci MT, Satriano RA, Mozzillo N, Castello G; Melanoma Cooperative Group of Naples. Ascierto PA, et al. Melanoma Res. 2002 Jun;12(3):293-6. doi: 10.1097/00008390-200206000-00015. Melanoma Res. 2002. PMID: 12140388 No abstract available.
[To outwit melanoma with its own tricks].
Bischoff A. Bischoff A. MMW Fortschr Med. 2003 Apr 10;145(15):4-6, 8, 10. MMW Fortschr Med. 2003. PMID: 15104255 Review. German. No abstract available.
Update on the role of adjuvant interferon for high risk melanoma.
Agarwala SS, Kirkwood JM. Agarwala SS, et al. Forum (Genova). 2000 Jul-Sep;10(3):230-9. Forum (Genova). 2000. PMID: 11007931 Review.

See all similar articles

Cited by

Interferon alpha for the adjuvant treatment of cutaneous melanoma.
Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Mocellin S, et al. Cochrane Database Syst Rev. 2013 Jun 18;2013(6):CD008955. doi: 10.1002/14651858.CD008955.pub2. Cochrane Database Syst Rev. 2013. PMID: 23775773 Free PMC article.
Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.
Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, Koruth R, Guérin A, Burne R, Ionescu-Ittu R, Perrinjaquet M, Zager JS. Mohr P, et al. Melanoma Manag. 2019 Oct 4;6(4):MMT33. doi: 10.2217/mmt-2019-0015. Melanoma Manag. 2019. PMID: 31871622 Free PMC article.
Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy.
Ng G, Xu W, Atkinson V. Ng G, et al. Curr Oncol Rep. 2022 Oct;24(10):1273-1280. doi: 10.1007/s11912-022-01288-y. Epub 2022 May 31. Curr Oncol Rep. 2022. PMID: 35639333 Free PMC article. Review.
Role of tumor-associated neutrophils in regulation of tumor growth in lung cancer development: A mathematical model.
Kim Y, Lee D, Lee J, Lee S, Lawler S. Kim Y, et al. PLoS One. 2019 Jan 28;14(1):e0211041. doi: 10.1371/journal.pone.0211041. eCollection 2019. PLoS One. 2019. PMID: 30689655 Free PMC article.
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.
Wang XY, Zuo D, Sarkar D, Fisher PB. Wang XY, et al. Expert Opin Pharmacother. 2011 Dec;12(17):2695-706. doi: 10.1517/14656566.2011.629187. Expert Opin Pharmacother. 2011. PMID: 22077831 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information